Pfizer (PFE) EBITDA (2009 - 2026)

Pfizer (PFE) has reported EBITDA for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 15.58% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $20.4 billion, a 22.57% decrease from a year earlier, with the FY2025 full-year figure at $20.7 billion, up 16.43% from the prior year.
• EBITDA was $4.3 billion for Q2 2026 at Pfizer, down from $5.4 billion in the prior quarter.
• Over five years, EBITDA peaked at $14.0 billion in Q3 2024 and troughed at -$14.1 billion in Q4 2023.
• A 5-year average of $5.2 billion and a median of $5.2 billion in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 73.85% in 2023 and soared 118.13% in 2025, its largest moves.
• Over 5 years, EBITDA stood at $13.0 billion in 2022, then sank by 208.0% to -$14.1 billion in 2023, then surged by 199.47% to $14.0 billion in 2024, then tumbled by 69.22% to $4.3 billion in 2025, then retreated by 1.09% to $4.3 billion in 2026.
• The last three EBITDA figures came in at $4.3 billion (Q2 2026), $5.4 billion (Q1 2026), and $4.3 billion (Q4 2025), per Business Quant data.